- Home
- TNXP vs IAUX Comparison
TNXP vs IAUX Comparison
Compare TNXP & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- IAUX
- Stock Information
- Founded
- TNXP 2007
- IAUX 2020
- Country
- TNXP United States
- IAUX United States
- Employees
- TNXP N/A
- IAUX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- IAUX
- Sector
- TNXP Health Care
- IAUX
- Exchange
- TNXP Nasdaq
- IAUX Nasdaq
- Market Cap
- TNXP 272.0M
- IAUX 253.2M
- IPO Year
- TNXP N/A
- IAUX N/A
- Fundamental
- Price
- TNXP $35.48
- IAUX $0.63
- Analyst Decision
- TNXP Strong Buy
- IAUX Buy
- Analyst Count
- TNXP 2
- IAUX 1
- Target Price
- TNXP $585.00
- IAUX $1.50
- AVG Volume (30 Days)
- TNXP 729.5K
- IAUX 12.3M
- Earning Date
- TNXP 08-15-2025
- IAUX 08-11-2025
- Dividend Yield
- TNXP N/A
- IAUX N/A
- EPS Growth
- TNXP N/A
- IAUX N/A
- EPS
- TNXP N/A
- IAUX N/A
- Revenue
- TNXP $10,041,000.00
- IAUX $55,970,000.00
- Revenue This Year
- TNXP $11.66
- IAUX $108.70
- Revenue Next Year
- TNXP $793.18
- IAUX $60.68
- P/E Ratio
- TNXP N/A
- IAUX N/A
- Revenue Growth
- TNXP N/A
- IAUX N/A
- 52 Week Low
- TNXP $6.76
- IAUX $0.34
- 52 Week High
- TNXP $130.00
- IAUX $1.26
- Technical
- Relative Strength Index (RSI)
- TNXP 52.96
- IAUX 50.92
- Support Level
- TNXP $33.71
- IAUX $0.59
- Resistance Level
- TNXP $38.13
- IAUX $0.65
- Average True Range (ATR)
- TNXP 2.62
- IAUX 0.04
- MACD
- TNXP -0.44
- IAUX -0.01
- Stochastic Oscillator
- TNXP 61.01
- IAUX 29.44
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.